Rheumatoid Arthritis

Top Story

Medical costs for RA three-fold higher among biologic DMARD users

January 18, 2018
In the Journals

Subsequent RA treatment varies after discontinuing methotrexate monotherapy

January 17, 2018
Patients with rheumatoid arthritis who discontinued methotrexate monotherapy were more likely to receive subsequent monotherapy treatment than those who had used the…

FDA accepts application for new Humira biosimilar

January 16, 2018
Sandoz announced that the FDA has accepted a biologics license application for a proposed biosimilar of the anti-inflammatory drug adalimumab, known commercially as…
In the Journals

Methotrexate alone yields similar outcomes to combined therapy for initial RA treatment

January 5, 2018
Initial methotrexate monotherapy, adding a TNF inhibitor at 26 weeks, produced long-term results similar to initial combined therapy among patients with early rheumatoid…
More Headlines »
CME CPE

Overcoming Barriers and Best Practices for Use of Biosimilars: Conversations Between Physicians and Pharmacists

This activity is supported by an educational grant from Pfizer, Inc.

As more biosimilars are approved for use in the United States, all members of the multidisciplinary care team will…
More »
Video
Meeting News

VIDEO: No increased cardiovascular risk among RA patients who start tocilizumab

November 30, 2017
More »
Resource Centers
American College of Rheumatology Annual Meeting

American College of Rheumatology Annual Meeting

CME ABIM MOC

Ace the Case: A 50-Year-Old Woman Presents with Joint Pain

There is no commercial support for this activity.

This “Ace the Case” study will explore the diagnosis and treatment of a 50-year-old woman who presents for an…
More »